NCT01043146View on ClinicalTrials.gov

Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide

PHASE1CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Heart Failure

Interventions

DRUG

COR-1

single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1

DRUG

placebo

intravenous 0.9 % NaCl

Trial Locations (1)

02826

ABX-CRO, Görlitz

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Corimmun GmbH

INDUSTRY